Skip to main content
. 2020 Sep 15;12(9):5511–5524.

Figure 1.

Figure 1

Comparisons of tumor volume, metastasis status, ascites, and accumulating survival among the CSM-ATO, cTACE-ATO, TAE-CSM, and control groups. A: Comparison of tumor volume in VX2 liver tumor rabbits among the CSM-ATO, cTACE-ATO, TAE-CSM, and control groups. B: Comparison of metastasis status and ascites in VX2 liver tumor rabbits among the CSM-ATO, cTACE-ATO, TAE-CSM, and control groups. C: Comparison of accumulating survival in VX2 liver tumor rabbits among the CSM-ATO, cTACE-ATO, TAE-CSM, and control groups. 14 d: 14 days; CSM: CalliSpheres® microspheres; ATO: arsenic trioxide; cTACE: conventional transarterial chemoembolization; TAE: transcatheter arterial embolization; **, P<0.01; *, P<0.05; NS, not significant.